Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Oriana NanniD AmadoriA De CensiA RoccaA FreschiA BolognaL GianniF RosettiL AmaducciL CavannaF FocaS SartiP SerraL ValmorriP BruzziD CorradengoA Gennarinull nullPublished in: Breast cancer research and treatment (2018)
The MYME trial failed to provide evidence in support of an anticancer activity of M in combination with first line CT in MBC. A significantly shorter PFS was observed in insulin-resistant patients (HOMA ≥ 2.5). Noteworthy, M had a significant effect on CT induced severe neutropenia. Further development of M in combination with CT in the setting of MBC is not warranted.
Keyphrases
- clinical trial
- image quality
- dual energy
- phase iii
- metastatic breast cancer
- computed tomography
- phase ii
- contrast enhanced
- double blind
- open label
- end stage renal disease
- ejection fraction
- type diabetes
- positron emission tomography
- study protocol
- newly diagnosed
- magnetic resonance imaging
- locally advanced
- peritoneal dialysis
- prognostic factors
- placebo controlled
- drug induced
- early onset
- magnetic resonance
- adipose tissue
- metabolic syndrome
- endothelial cells
- insulin resistance